Development of antibody therapeutics using proprietary chicken antibody technology
First written in FY2016-Q3. 19 of 32 entries say "Advanced", first in FY2018-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In the cancer field, we aim to build various pipelines led by antibodies targeting cancer-specific expression proteins introduced from Tohoku University, hereinafter referred to as AviOn antibodies.」
The Company added the cancer-specific AviOn antibody introduced from Tohoku University to its ALAgene technology-based drug discovery pipeline and is advancing preclinical research and partnering activities. The Company also described the establishment of an integrated platform through a 5-year AMED project. - FY2024AdvancedAnnual report
「For this antibody drug candidate, Mitsubishi Tanabe Pharma Corporation submitted the initial clinical trial notification to the Pharmaceuticals and Medical Devices Agency (PMDA), and the 30-day review was completed. As a result, in June 2024 we received the milestone payment stipulated under the licensing agreement.」
For the antibody drug candidate for autoimmune diseases, we received milestone revenue under the licensing agreement in June 2024 following Mitsubishi Tanabe Pharma’s submission of the initial clinical trial notification and completion of PMDA’s 30-day review. - FY2024-Q3AdvancedAnnual report
「We are also actively pursuing AI-based drug discovery through a specialist team. As a result, in February 2024 we obtained Patent No. 7437558 for technology that enables antibodies to be produced more efficiently by modifying antigens through computer-aided design.」
The acquisition of patents for antigen design and antibody production technologies in AI drug discovery has advanced the protection of drug discovery technologies based on ALAgene technology. - FY2024-Q1AdvancedAnnual report
「For various intractable diseases, including “fibrosis,” we are obtaining and purifying antibodies against target molecules and advancing drug discovery research, including pharmacological efficacy studies. We are also actively pursuing joint research with academic institutions that have novel drug discovery seeds, and research and development using Aladdin Technology is progressing steadily toward expanding our drug discovery pipeline.」
In addition to autoimmune diseases, we are obtaining and purifying antibodies and conducting pharmacological efficacy studies for intractable diseases, including fibrosis, while also pursuing joint research with academic institutions that have novel drug discovery seeds. - FY2023AdvancedAnnual report
「In this business, we are participating as a key member of the Japan Agency for Medical Research and Development (AMED) FY2021 project, “Drug Discovery Platform Technology Development for Next-Generation Therapeutics and Diagnostics (Development of Globally Competitive Manufacturing Technologies for Next-Generation Antibody Drugs).” In this business, we successfully obtained lead antibodies that could serve as candidates for next-generation antibody drugs targeting all diseases and have proceeded to the development process for next-generation antibody drugs, including small-format antibodies and bispecific antibodies.」
In the development of next-generation antibodies based on ALAgene technology, we have described our participation in the AMED project, our successful acquisition of lead antibodies, and our transition to the development process for next-generation antibodies. - FY2023-Q2AdvancedAnnual report
「In our drug discovery business, we conduct research and development targeting intractable diseases, including “autoimmune diseases” and “fibrosis.” ALAgene technology, which forms the foundation of our drug discovery business, is our proprietary platform technology for producing antibodies against diseases that have previously been untreatable and antibodies with superior efficacy to existing drugs.」
In addition to autoimmune diseases, we have identified “fibrosis” and other conditions as drug discovery research targets and continue research and development for intractable diseases based on ALAgene technology. - FY2023-Q1AdvancedAnnual report
「For the anti-PAD4 antibody, we received a notice of allowance from the United States Patent and Trademark Office in August 2022 (application number US15/555,808). This patent allowance strengthened the intellectual property rights for the drug discovery project targeting “PAD4” not only in Japan (Patent Nos. 6369922 and 6675739), but also in the United States, which accounts for 50% of the global biopharmaceutical market.」
For drug discovery targeting autoimmune diseases, we received allowance of the US patent for the anti-PAD4 antibody, strengthening our intellectual property rights in the United States. - FY2022AdvancedAnnual report
「By combining “ALAgene® technology” with proteome analysis technology, we aim to strengthen the search for and identification of drug discovery targets and accelerate the development of the world’s first antibody drugs. In addition, we have newly formed a specialist AI team to shorten the process from target discovery through antibody design.」
In addition to the succession of Integral’s bioscience business, we are incorporating proteome analysis and a specialist AI team into our drug discovery platform and moving toward shorter discovery and design processes. - FY2022-Q3AdvancedAnnual report
「“ALAgene® technology” is a technology for producing antibodies against diseases that have previously been untreatable and antibodies with superior efficacy to existing drugs. We achieved licensing out to pharmaceutical companies ahead of our competitors.」
We are reconfirming our track record of licensing out ALAgene technology to pharmaceutical companies and expanding into enhanced drug discovery by combining it with Integral’s proteome analysis technology and AI. - FY2022-Q2RestatedAnnual report
「“ALAgene® technology” is a technology for producing antibodies against diseases that have previously been untreatable and antibodies with superior efficacy to existing drugs. We achieved licensing out to pharmaceutical companies ahead of our competitors.」
We are reconfirming our track record in antibody drug discovery using ALAgene technology and licensing out to pharmaceutical companies. - FY2022-Q1AdvancedAnnual report
「In particular, for the anti-PAD2 antibody, we are advancing various pharmacological efficacy studies and negotiations for partnerships with major domestic and overseas pharmaceutical companies. For various intractable diseases, including malignant tumors, we are conducting pharmacological efficacy studies using anti-FSTL1 antibodies and other agents and advancing negotiations for partnerships with major pharmaceutical companies.」
For autoimmune diseases, we are advancing pharmacological efficacy studies of various anti-PAD2 antibodies and negotiations for partnerships with major pharmaceutical companies. For malignant tumors and other conditions, we are advancing pharmacological efficacy studies using anti-FSTL1 antibodies and other agents, as well as partnership negotiations. - FY2021AdvancedAnnual report
「As a result of the high evaluation of the usefulness of our technology for producing superior antibodies in these projects, we were selected in June 2021 for the Japan Agency for Medical Research and Development (AMED) FY2021 project, “Drug Discovery Platform Technology Development for Next-Generation Therapeutics and Diagnostics (Development of Globally Competitive Manufacturing Technologies for Next-Generation Antibody Drugs).”」
We were selected by AMED for a project to develop manufacturing technologies for next-generation antibody drugs targeting all diseases by leveraging and advancing ALAgene technology. - FY2021-Q3RestatedAnnual report
「In the Autoimmune Disease Project, the company conducted joint research on antibody drugs with Mitsubishi Tanabe Pharma Corporation for 2 years from October 2018. Based on the results, the company and Mitsubishi Tanabe Pharma Corporation entered into an exclusive license agreement in January 2021. Going forward, the company will receive development milestone payments according to the stage of development. If this antibody drug is launched in the global antibody-drug market for autoimmune diseases, which is worth as much as ¥5 trillion, the company will also receive royalties based on worldwide sales and sales milestone payments.」
The company is reaffirming the framework for development and monetization following the signing of an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the autoimmune disease antibody drug. - FY2021-Q2AdvancedAnnual report
「Based on these results, the company and Mitsubishi Tanabe Pharma Corporation entered into an exclusive license agreement and decided to advance the antibody drug to the development stage.」
The company made concrete progress toward development by entering into an exclusive license agreement based on the joint research results for an autoimmune disease antibody drug using ALAgene technology. - FY2021-Q1AdvancedAnnual report
「In addition, for autoimmune diseases, we established the International PAD Research Center within our Drug Discovery Research Institute, promoted drug discovery research on a range of PAD-related targets, and made steady progress in expanding our drug discovery pipeline.」
In addition to drug discovery using ALAgene technology and other technologies, the company has established the International PAD Research Center to expand its drug discovery targets related to autoimmune diseases. - FY2020-Q3AdvancedAnnual report
「In the Malignant Tumor Project (target molecule: FSTL1), development has accelerated following the grant in the United States, in addition to Japan, of the patent concerning the anti-FSTL1 antibody filed in 2016, titled “Anticancer agent, metastasis inhibitor and combination agent using FSTL1.”」
The FSTL1 antibody-related patent was granted in the United States following Japan, advancing the Malignant Tumor Project's patent rights and development. - FY2020-Q2AdvancedAnnual report
「In the Malignant Tumor Project (target molecule: FSTL1), development has accelerated following the grant in Japan of the patent concerning the anti-FSTL1 antibody filed in 2016, titled “Anticancer agent, metastasis inhibitor and combination agent using FSTL1.” The company will continue conducting antitumor studies on various malignant tumor cells using the anti-FSTL1 antibody while continuing negotiations with pharmaceutical companies for a partnership.」
The FSTL1 antibody-related patent was granted in Japan, and the project has advanced to the development stage involving continued antitumor studies and partnership negotiations with pharmaceutical companies. - FY2020-Q1RestatedAnnual report
「The company's proprietary chicken-derived antibody generation technology, ALAgene® technology (Aladdin Technology), enables the acquisition of high-affinity antibodies against drug discovery target molecules that are difficult to generate using conventional technologies. The company conducts research and development of antibody drugs for autoimmune diseases and malignant tumors using humanized antibodies and other products generated through ALAgene® technology.」
The company continues research and development of antibody drugs for autoimmune diseases and malignant tumors using its proprietary avian-derived antibody technology. - FY2019-Q3RestatedAnnual report
「The company can obtain high-affinity antibodies against drug discovery target molecules that are difficult to obtain using conventional technologies through its proprietary avian-derived antibody acquisition technology, ALAgene technology (Aladdin Technology). It conducts research and development of antibody drugs for autoimmune diseases and malignant tumors using humanized antibodies and other products derived from avian antibodies.」
The company continues research into antibody drugs for autoimmune diseases and malignant tumors using its proprietary avian-derived antibody technology. - FY2019-Q2RestatedAnnual report
「The company can obtain high-affinity antibodies against drug discovery target molecules that are difficult to obtain using conventional technologies through its proprietary avian-derived antibody acquisition technology, ALAgene technology (Aladdin Technology). It conducts research and development of antibody drugs for autoimmune diseases and malignant tumors using humanized antibodies and other products derived from avian antibodies.」
The company continues research into antibody drugs for autoimmune diseases and malignant tumors using its proprietary avian-derived antibody technology. - FY2019-Q1RaisedAnnual report
「Under this agreement, the two companies will use their respective technologies to improve antibodies against drug discovery target molecules for autoimmune diseases created by the company, with the aim of creating new antibody drugs.」
In addition to the existing malignant tumor, rheumatoid arthritis and bone formation projects, the company has added antibody-drug creation targeting autoimmune diseases, broadening the scope of its drug discovery pipeline. - FY2018-Q3AdvancedAnnual report
「ReproTite was selected as a joint research project with the University of Tokyo under the Japan Agency for Medical Research and Development's FY2018 Practical Research Project for Rare and Intractable Diseases. The company will work with the University of Tokyo to assess ReproTite's potential as a drug discovery candidate for a treatment to improve bone fragility in osteogenesis imperfecta, with the aim of developing a pharmaceutical product.」
The ReproTite Bone Formation Project was selected as a joint research project with the University of Tokyo under AMED's FY2018 program and has advanced to the validation stage as a candidate treatment for osteogenesis imperfecta. - FY2018-Q2RestatedAnnual report
「In the drug discovery business, the company continued to focus on the Malignant Tumor Project (target molecule: FSTL1) and the Rheumatoid Arthritis Project (target molecule: PAD4), which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene (Aladdin / Avian Lead Antibody GENE), as well as the Bone Formation Project, which aims to develop a drug based on the egg-yolk-derived bone-forming peptide ReproTite.」
The company continues to focus on the malignant tumor and rheumatoid arthritis projects using ALA gene, and the Bone Formation Project using ReproTite. - FY2018-Q1RestatedAnnual report
「In the drug discovery business, the company continued to focus on the Malignant Tumor Project (target molecule: FSTL1) and the Rheumatoid Arthritis Project (target molecule: PAD4), which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene (Aladdin / Avian Lead Antibody GENE), as well as the Bone Formation Project, which aims to create novel peptide drugs.」
The company continues to focus on 3 projects using ALA gene: malignant tumors, rheumatoid arthritis and bone formation through a novel peptide drug. - FY2017-Q3RestatedAnnual report
「In the drug discovery business, the company has focused on the Malignant Tumor Project and the Rheumatoid Arthritis Project, which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene (Aladdin / Avian Lead Antibody GENE), as well as the Bone Formation Project, which aims to create novel peptide drugs.」
The company continues to focus on 3 projects using ALA gene: malignant tumors, rheumatoid arthritis and bone formation through a novel peptide drug. - FY2017-Q2RaisedAnnual report
「In the drug discovery business, the company has focused on the Malignant Tumor Project and the Rheumatoid Arthritis Project, which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene (Aladdin / Avian Lead Antibody GENE), as well as the Bone Formation Project, which aims to create novel peptide drugs.」
In addition to the existing antibody-drug projects for malignant tumors and rheumatoid arthritis, the company has specified the Bone Formation Project for a novel peptide drug, broadening the scope of its drug discovery pipeline. - FY2017-Q1RestatedAnnual report
「In the drug discovery business, the company has focused on the Malignant Tumor Project and the Rheumatoid Arthritis Project, which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene (Aladdin / Avian Lead Antibody GENE).」
The company continues to focus on both the malignant tumor and rheumatoid arthritis antibody-drug projects using its proprietary chicken antibody technology. - FY2016-Q3First statedAnnual report
「In the drug discovery business, the company is focusing on the Rheumatoid Arthritis Project and the Malignant Tumor Project, which aim to create novel antibody drugs using its proprietary chicken antibody generation technology, ALAgene® (Aladdin / Avian Lead Antibody GENE).」
The company is focusing on 2 projects, for rheumatoid arthritis and malignant tumors, using its proprietary antibody-generation technology.